176 related articles for article (PubMed ID: 17445796)
41. Renal and vascular protective effects of cilnidipine in patients with essential hypertension.
Morimoto S; Yano Y; Maki K; Iwasaka T
J Hypertens; 2007 Oct; 25(10):2178-83. PubMed ID: 17885563
[TBL] [Abstract][Full Text] [Related]
42. Ion channel modifying agents influence the electrical activity generated by canine intrinsic cardiac neurons in situ.
Thompson GW; Horackova M; Armour JA
Can J Physiol Pharmacol; 2000 Apr; 78(4):293-300. PubMed ID: 10772056
[TBL] [Abstract][Full Text] [Related]
43. Long-term blockade of L/N-type Ca(2+) channels by cilnidipine ameliorates repolarization abnormality of the canine hypertrophied heart.
Takahara A; Nakamura Y; Wagatsuma H; Aritomi S; Nakayama A; Satoh Y; Akie Y; Sugiyama A
Br J Pharmacol; 2009 Nov; 158(5):1366-74. PubMed ID: 19785655
[TBL] [Abstract][Full Text] [Related]
44. Effects of L/N-type calcium channel antagonist, cilnidipine on progressive renal injuries in Dahl salt-sensitive rats.
Konda T; Enomoto A; Takahara A; Yamamoto H
Biol Pharm Bull; 2006 May; 29(5):933-7. PubMed ID: 16651722
[TBL] [Abstract][Full Text] [Related]
45. T-type Ca2+ channel blockade prevents sudden death in mice with heart failure.
Kinoshita H; Kuwahara K; Takano M; Arai Y; Kuwabara Y; Yasuno S; Nakagawa Y; Nakanishi M; Harada M; Fujiwara M; Murakami M; Ueshima K; Nakao K
Circulation; 2009 Sep; 120(9):743-52. PubMed ID: 19687356
[TBL] [Abstract][Full Text] [Related]
46. Effect of oxodipine, a novel dihydropyridine calcium channel blocker, in neurogenic hypertensive dogs.
Montastruc P; Montastruc JL; Dubreuil J; Galiano A
Arch Int Pharmacodyn Ther; 1993; 321():57-62. PubMed ID: 8323416
[TBL] [Abstract][Full Text] [Related]
47. Effects of the L/N-Type Ca
Harada E; Sugino K; Aimoto M; Takahara A
Biol Pharm Bull; 2021 May; 44(5):707-713. PubMed ID: 33642455
[TBL] [Abstract][Full Text] [Related]
48. [Antihypertrophic effect of dihydropyridines calcium channel blockers is dependent on their potential of blocking N-type calcium channel].
Luo Q; Xuan WL; Xi F; Liao YL; Kitakaze M
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Apr; 30(4):755-9. PubMed ID: 20423843
[TBL] [Abstract][Full Text] [Related]
49. Anti-proteinuric effect of an N-type calcium channel blocker, cilnidipine.
Tsuchihashi T; Ueno M; Tominaga M; Kajioka T; Onaka U; Eto K; Goto K
Clin Exp Hypertens; 2005 Nov; 27(8):583-91. PubMed ID: 16303635
[TBL] [Abstract][Full Text] [Related]
50. Effects of L- and N-Type Ca Channel Blocker Cilnidipine on Changes in Heart Rate and QT Interval During Dialysis.
Iida T; Morimoto S; Amari Y; Ando T; Ichihara A
Kidney Blood Press Res; 2017; 42(5):933-941. PubMed ID: 29166643
[TBL] [Abstract][Full Text] [Related]
51. Cilnidipine is a novel slow-acting blocker of vascular L-type calcium channels that does not target protein kinase C.
Löhn M; Muzzulini U; Essin K; Tsang SY; Kirsch T; Litteral J; Waldron P; Conrad H; Klugbauer N; Hofmann F; Haller H; Luft FC; Huang Y; Gollasch M
J Hypertens; 2002 May; 20(5):885-93. PubMed ID: 12011649
[TBL] [Abstract][Full Text] [Related]
52. The structure-activity relationship study on 2-, 5-, and 6-position of the water soluble 1,4-dihydropyridine derivatives blocking N-type calcium channels.
Yamamoto T; Niwa S; Ohno S; Tokumasu M; Masuzawa Y; Nakanishi C; Nakajo A; Onishi T; Koganei H; Fujita S; Takeda T; Kito M; Ono Y; Saitou Y; Takahara A; Iwata S; Shoji M
Bioorg Med Chem Lett; 2008 Sep; 18(17):4813-6. PubMed ID: 18684623
[TBL] [Abstract][Full Text] [Related]
53. Neuronal Ca2+ channel blocking action of an antihypertensive drug, cilnidipine, in IMR-32 human neuroblastoma cells.
Takahara A; Fujita S; Moki K; Ono Y; Koganei H; Iwayama S; Yamamoto H
Hypertens Res; 2003 Sep; 26(9):743-7. PubMed ID: 14620931
[TBL] [Abstract][Full Text] [Related]
54. Cilnidipine attenuates renal nerve stimulation-induced renal vasoconstriction and antinatriuresis in anesthetized dogs.
Takahara A; Dohmoto H; Hisa H; Satoh S; Yoshimoto R
Jpn J Pharmacol; 1997 Sep; 75(1):27-32. PubMed ID: 9334883
[TBL] [Abstract][Full Text] [Related]
55. The effect of an L/N-type calcium channel blocker on intradialytic blood pressure in intradialytic hypertensive patients.
Ito T; Fujimoto N; Ishikawa E; Dohi K; Fujimoto M; Murata T; Kiyohara M; Takeuchi H; Koyabu S; Nishimura H; Takeuchi T; Ito M
Clin Exp Hypertens; 2019; 41(1):92-99. PubMed ID: 29584458
[TBL] [Abstract][Full Text] [Related]
56. Increased vascular selectivity and prolonged pharmacological efficacy of the L-type Ca2+ channel antagonist lercanidipine in human cardiovascular tissue.
Brixius K; Gross T; Tossios P; Geissler HJ; Mehlhorn U; Schwinger RH; Hekmat K
Clin Exp Pharmacol Physiol; 2005 Sep; 32(9):708-13. PubMed ID: 16173926
[TBL] [Abstract][Full Text] [Related]
57. [Calcium antagonists: current and future applications based on new evidence. Cardio-protective effect of calcium antagonists].
Hongo K; Yoshimura M
Clin Calcium; 2010 Jan; 20(1):89-93. PubMed ID: 20048439
[TBL] [Abstract][Full Text] [Related]
58. Stress-induced blood pressure elevation in subjects with mild cognitive impairment: effects of the dual-type calcium channel blocker, cilnidipine.
Kawashima Y; Akishita M; Hasegawa H; Kozaki K; Toba K
Geriatr Gerontol Int; 2008 Dec; 8(4):278-83. PubMed ID: 19149840
[TBL] [Abstract][Full Text] [Related]
59. Selectivity of dihydropyridines for cardiac L-type and sympathetic N-type Ca2+ channels.
Uneyama H; Uchida H; Konda T; Yoshimoto R; Akaike N
Eur J Pharmacol; 1999 May; 373(1):93-100. PubMed ID: 10408255
[TBL] [Abstract][Full Text] [Related]
60. Switching to an L/N-type calcium channel blocker shows renoprotective effects in patients with chronic kidney disease: the Kyoto Cilnidipine Study.
Hatta T; Takeda K; Shiotsu Y; Sugishita C; Adachi T; Kimura T; Sonomura K; Kusaba T; Kishimioto N; Narumiya H; Tanda S; Tamagaki K; Yamada K; Kameyama H; Kido H; Harada S; Bito Y; Moriguchi J; Morimoto S; Okigaki M; Itoh H; Mori Y; Nakata T; Maki K; Sasaki S; Sawada K; Matsubara H
J Int Med Res; 2012; 40(4):1417-28. PubMed ID: 22971493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
